Finance

Beta
Lists
KROS:NASDAQ
Keros Therapeutics Inc
$10.93
-0.55%
(-0.060) 1D
$10.93
0.00% (0.00)
After hours
Closed: Jun 29, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KROS...
Open
$10.92
High
$10.96
Low
$10.57
Mkt. cap
216.32M
Avg. vol.
337.36K
Volume
352.80K
52-wk high
$22.55
52-wk low
$9.69
EPS
-$3.01
Beta
0.94
Shares outstanding
19.79M
No. of employees
87
Open
$10.92
High
$10.96
Low
$10.57
Mkt. cap
216.32M
Avg. vol.
337.36K
Volume
352.80K
52-wk high
$22.55
52-wk low
$9.69
EPS
-$3.01
Beta
0.94
Shares outstanding
19.79M
No. of employees
87
News stories
From sources across the web
About Keros Therapeutics Inc
CEO-
Employees87
Founded2015
HeadquartersLexington, Massachusetts, United States
SectorBiotechnology
Websitekerostx.com
Analyst ratings
Based on 7 analysts giving stock ratings to KROS in the past 3 months
Buy
Buy
3
Hold
4
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for KROS in the last 3 months.
Highest
Current $10.93
$20.00 (+82.98%)
Average
$19.00 (+73.83%)
Lowest
$16.00 (+46.39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Zemansky
Bank of America Securities
Hold
Reiterated
$20.00
+83%
06/03/2026
Yun Zhong
Wedbush
Hold
Maintained
$16.00
+46.4%
05/19/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
05/15/2026
Nicholas Lorusso
TD Cowen
Hold
Maintained
-
-
05/14/2026
Benjamin Burnett
Wells Fargo
Buy
Maintained
$20.00
+83%
05/15/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$20.00
+83%
05/15/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
05/14/2026
Andreas Argyrides
Oppenheimer
Buy
Maintained
$27.00
+147%
03/09/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$30.00
+174.5%
03/06/2026
Tiago Fauth
Raymond James
Buy
Maintained
$20.00
+83%
03/05/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
18.17M
14.26M
385.00K
367.00K
Cost of goods sold
43.50M
19.52M
17.81M
16.10M
Cost of revenue
43.50M
19.52M
17.81M
16.10M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.48M
10.13M
11.74M
10.15M
Operating expense
14.48M
10.13M
11.74M
10.15M
Total operating expenses
57.98M
29.65M
29.56M
26.24M
Operating income
-39.82M
-15.38M
-29.17M
-25.88M
Other non operating income
-
-
-539.00K
-
EBT including unusual items
-32.92M
-8.70M
-24.98M
-23.71M
EBT excluding unusual items
-32.92M
-8.70M
-24.88M
-23.71M
Income tax expense
-2.22M
-1.42M
-1.51M
-
Effective tax rate
6.75%
16.36%
6.06%
-
Other operating expenses
-
-
-
-
Net income
-30.70M
-7.28M
-23.46M
-23.71M
Net profit margin
-168.96%
-51.04%
-6,093.77%
-6,459.95%
Earnings per share
-0.76
-0.18
-0.86
-1.21
Interest and investment income
7.12M
6.93M
4.02M
2.34M
Interest expense
-
-
-
-
Net interest expenses
7.12M
6.93M
4.02M
2.34M
Depreciation and amortization charges
-
-
-
-
EBITDA
-39.45M
-14.99M
-28.77M
-25.47M
Gain or loss from assets sale
-14.00K
-
1.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer